Asthma - Pipeline Review, H2 2011

Published by: Global Markets Direct

Published: Sep. 28, 2011 - 189 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Asthma Overview
Therapeutics Development
An Overview of Pipeline Products for Asthma
Asthma Therapeutics under Development by Companies
Asthma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Asthma Therapeutics - Products under Development by Companies
Asthma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Asthma Therapeutics Development
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Clinical Data, Inc.
Abbott Laboratories
Shionogi & Co., Ltd.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc
MedImmune LLC
Merck & Co., Inc.
United Biomedical, Inc.
Synairgen plc
Orexo AB
RXi Pharmaceuticals Corporation
InDex Pharmaceuticals AB
Verona Pharma Plc
Affimed Therapeutics AG
Alba Therapeutics Corporation
Immupharma Plc
Palau Pharma S.A
Actimis Pharmaceuticals, Inc.
7TM Pharma A/S
Pieris AG
Respiratorius AB
Intracel Resources, LLC
KaloBios Pharmaceuticals, Inc.
AB Science
Resolvyx Pharmaceuticals, Inc
KYORIN Pharmaceutical Co., Ltd.
Aerovance, Inc.
NexBio, Inc.
Medigreen Biotechnology Corporation
Endacea, Inc.
Kemin Industries, Inc.
Asmacure Limited
Yoo Young Pharmaceutical Co., Ltd.
Cellceutix Pharmaceuticals, Inc.
Interprotein Corporation
N30 Pharmaceuticals
Eurofarma
Mankind Pharma Limited
DOLTHERA GmbH
EmphyCorp, Inc.
Immune Technologies and Medicine
Asklepion Pharmaceuticals, LLC.
Asthma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Cinquil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flutiform - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK642444 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relovair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Achipex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAP0010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spiriva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KCA-757 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTR-15K - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tulobuterol Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Inflammatory - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Formoterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Asthma Therapeutics - Drug Profile Updates
Asthma Therapeutics - Discontinued Products
Asthma - Featured News
Sep 14, 2011: AB Science Receives FDA IND Status For Masitinib
Aug 17, 2011: Cytos Biotechnology Announces Strategic And Organizational Changes
Aug 17, 2011: Verona Pharma Provides Update On Phase II Study Of RPL554
Aug 15, 2011: Pulmatrix Invests In Clinical Programs in COPD and Cystic Fibrosis
Aug 15, 2011: Pulmatrix Secures a $14 million Financing To Advance Clinical Programs In COPD And Cystic Fibrosis
Aug 10, 2011: Glenmark Initiates Phase IIb Human Trials Globally For Revamilast
Aug 04, 2011: Roche’s Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease
Jul 18, 2011: Synairgen Announces Issuance Of Patent In Japan
Jun 21, 2011: Palatin Technologies Receives US Patent For Key Component In PL-3994 Drug Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Asthma, H2 2011
Products under Development for Asthma - Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Kyowa Hakko Kirin Co., Ltd., H2 2011
Clinical Data, Inc., H2 2011
Abbott Laboratories, H2 2011
Shionogi & Co., Ltd., H2 2011
Amgen Inc., H2 2011
AstraZeneca PLC, H2 2011
GlaxoSmithKline plc, H2 2011
MedImmune LLC, H2 2011
Merck & Co., Inc., H2 2011
United Biomedical, Inc., H2 2011
Dainippon Sumitomo Pharma Co., Ltd., H2 2011
SkyePharma PLC, H2 2011
Acusphere, Inc., H2 2011
Novagali Pharma SA, H2 2011
Teijin Pharma Limited, H2 2011
Novartis AG, H2 2011
Actelion Ltd, H2 2011
Cephalon, Inc., H2 2011
Chiesi Farmaceutici SpA, H2 2011
Dong-A Pharmaceutical Co., Ltd., H2 2011
Glenmark Pharmaceuticals Ltd., H2 2011
Ono Pharmaceutical Co., Ltd., H2 2011
Orion Corporation, H2 2011
Pfizer Inc., H2 2011
Rigel Pharmaceuticals, Inc., H2 2011
Genmab A/S, H2 2011
Sun Pharmaceutical Industries Limited, H2 2011
Exelixis, Inc., H2 2011
Paratek Pharmaceuticals, Inc., H2 2011
PARI Pharma GmbH, H2 2011
Icagen Inc, H2 2011
Antisense Therapeutics Limited, H2 2011
Idera Pharmaceuticals, Inc., H2 2011
Lotus Pharmaceuticals, Inc., H2 2011
Almirall, S.A., H2 2011
Lpath, Inc., H2 2011
MediciNova, Inc., H2 2011
Biota Holdings Limited, H2 2011
Compugen Ltd., H2 2011
Pacgen Biopharmaceuticals Corporation, H2 2011
Palatin Technologies, Inc., H2 2011
Pharmaxis Ltd., H2 2011
MAP Pharmaceuticals, Inc., H2 2011
Alexion Pharmaceuticals, Inc., H2 2011
Cytokinetics, Inc, H2 2011
Regeneron Pharmaceuticals, Inc., H2 2011
SciClone Pharmaceuticals, Inc., H2 2011
Dynavax Technologies Corporation, H2 2011
Phytopharm Plc, H2 2011
Hanall Pharmaceutical Co., Ltd., H2 2011
Cytos Biotechnology AG, H2 2011
Ahn-Gook Pharmaceutical Co., Ltd., H2 2011
Biotie Therapies Corp., H2 2011
Neurim Pharmaceuticals (1991) Ltd., H2 2011
Synairgen plc, H2 2011
Orexo AB, H2 2011
RXi Pharmaceuticals Corporation, H2 2011
InDex Pharmaceuticals AB, H2 2011
Verona Pharma Plc, H2 2011
Affimed Therapeutics AG, H2 2011
Alba Therapeutics Corporation, H2 2011
Immupharma Plc, H2 2011
Palau Pharma S.A, H2 2011
Actimis Pharmaceuticals, Inc., H2 2011
7TM Pharma A/S, H2 2011
Pieris AG, H2 2011
Respiratorius AB, H2 2011
Cosmix Molecular Biologicals GmbH, H2 2011
Aquinox Pharmaceuticals Inc., H2 2011
Circassia Holdings Ltd., H2 2011
Funxional Therapeutics Ltd, H2 2011
ZaBeCor Pharmaceuticals, H2 2011
Promedior, Inc., H2 2011
Oxagen Limited, H2 2011
Clinquest Group, B.V., H2 2011
Heat Biologics, Inc., H2 2011
Pulmatrix, Inc., H2 2011
Opsona Therapeutics Ltd., H2 2011
Rottapharm SpA, H2 2011
Amira Pharmaceuticals, Inc., H2 2011
Indus Biotech Private Limited, H2 2011
AIM Therapeutics Inc., H2 2011
Hydra Biosciences, Inc., H2 2011
NovImmune SA, H2 2011
Txcell SA, H2 2011
Theraclone Sciences, Inc., H2 2011
Vantia Therapeutics, H2 2011
Biotica Technology Ltd, H2 2011
Inverseon, Inc., H2 2011
Xencor, Inc., H2 2011
Targacept, Inc., H2 2011
BaroFold, Inc., H2 2011
Sparsha Pharma International Pvt. Ltd., H2 2011
Intracel Resources, LLC, H2 2011
KaloBios Pharmaceuticals, Inc., H2 2011
AB Science, H2 2011
Resolvyx Pharmaceuticals, Inc, H2 2011
KYORIN Pharmaceutical Co., Ltd., H2 2011
Aerovance, Inc., H2 2011
NexBio, Inc., H2 2011
Medigreen Biotechnology Corporation, H2 2011
Endacea, Inc., H2 2011
Kemin Industries, Inc., H2 2011
Asmacure Limited, H2 2011
Yoo Young Pharmaceutical Co., Ltd., H2 2011
Cellceutix Pharmaceuticals, Inc., H2 2011
Interprotein Corporation, H2 2011
N30 Pharmaceuticals, H2 2011
Eurofarma, H2 2011
Mankind Pharma Limited, H2 2011
DOLTHERA GmbH, H2 2011
EmphyCorp, Inc., H2 2011
Immune Technologies and Medicine, H2 2011
Asklepion Pharmaceuticals, LLC., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Asthma Therapeutics - Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Asthma, H2 2011
Products under Development for Asthma - Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Abstract

Asthma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2011', provides an overview of the Asthma therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. 'Asthma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Asthma.
  • A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Asthma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Asthma therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.